Share on LinkedInShare on LinkedIn

ARTICLE · 18 MAY 2022

To Err Is Human, To Forgive Divine – If There Was Error

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In Apotex, Inc. v. Auspex Pharms., Inc., IPR2021-01507, Paper 9 (P.T.A.B. March 9, 2022), the Patent Trial and Appeal Board exercised its discretion under 35 U.S.C. § 325(d) to deny institution of Apotex's petition for inter partes review.

United StatesIntellectual Property

Holding

In Apotex, Inc. v. Auspex Pharms., Inc., IPR2021-01507, Paper 9 (P.T.A.B. March 9, 2022) ("Institution Decision"), the Patent Trial and Appeal Board ("PTAB") exercised its discretion under 35 U.S.C. § 325(d) to deny institution of Apotex's petition for inter partes review ("IPR").

Background

Apotex (hereinafter "Petitioner") filed an IPR petition challenging claims 1-3 of Auspex's (hereinafter "Patent Owner") U.S. Pat. No. 8,524,733. Claims 1 and 2 are compound claims, while claim 3 is a composition claim. The claims are directed to "a specific deuteration pattern in tetrabenazine that ... does not involve deuteration of the carbon-hydrogen bonds of the carbonyl group, the isopropyl group, or any other carbon-hydrogen position in the molecule." Institution Decision at *6 (emphasis in original).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from